MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
August 04 2020 - 6:30AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced
that MediciNova will participate in the Morgan
Stanley Virtual 18th Annual Global Healthcare Conference which
will be held from September 14 - 18, 2020. Yuichi Iwaki,
MD, PhD, President and Chief Executive Officer, and Geoffrey
O'Brien, JD/MBA, Vice President and Executive Officer, will be
available for one-on-one meetings at this conference and investors
may request a one-on-one meeting through Morgan Stanley.
About MediciNova
MediciNova, Inc. is a publicly traded biopharmaceutical company
focused on developing novel therapeutics for the treatment of
diseases with high unmet medical needs with a primary commercial
focus on the U.S. market. MediciNova's current strategy is to
focus on BC-PIV vaccine for COVID-19, MN-166 (ibudilast) for
neurological disorders such as progressive multiple sclerosis (MS),
amyotrophic lateral sclerosis (ALS), degenerative cervical
myelopathy (DCM), glioblastoma (GBM), and substance dependence
(e.g., alcohol use disorder, methamphetamine dependence, opioid
dependence), as well as prevention of acute respiratory distress
syndrome (ARDS) caused by COVID-19, and MN-001 (tipelukast) for
fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and
idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline
also includes MN-221 (bedoradrine) and MN-029 (denibulin).
For more information on MediciNova, Inc., please visit
www.medicinova.com.
Statements in this press release that are not historical in
nature constitute forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements regarding the future development and
efficacy of BC-PIV vaccine, MN-166, MN-001, MN-221, and MN-029.
These forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2019 and its subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Undue reliance should not be
placed on these forward-looking statements, which speak only as of
the date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT: Geoff O'BrienVice PresidentMediciNova,
Inc.info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Apr 2023 to Apr 2024